Effect of SARS-CoV-2 mRNA vaccination in MS patients treated with disease modifying therapies.

ABSTRACT:

Background

In patients with Multiple Sclerosis (pwMS) disease-modifying therapies (DMTs) affects immune response to antigens. Therefore, post-vaccination serological assessments are needed to evaluate the effect of the vaccine on SARS-CoV-2 antibody response.

Methods

We designed a prospective multicenter cohort study enrolling pwMS who were scheduled for SARS-Cov-2 vaccination with mRNA vaccines (BNT162b2, Pfizer/BioNTech,Inc or mRNA-1273, Moderna Tx,Inc). A blood collection before the first vaccine dose and 4 weeks after the second dose was planned, with a centralized serological assessment (electrochemiluminescence immunoassay, ECLIA, Roche-Diagnostics). The log-transform of the antibody levels was analyzed by multivariable linear regression.

Findings

780 pwMS (76%

SUBMITTER: Sormani MP 

PROVIDER: S-EPMC8456129 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature